Zymeworks Statistics
Total Valuation
Zymeworks has a market cap or net worth of $1.44 billion. The enterprise value is $1.12 billion.
Important Dates
The next confirmed earnings date is Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zymeworks has 75.17 million shares outstanding. The number of shares has increased by 2.47% in one year.
| Current Share Class | 75.17M |
| Shares Outstanding | 75.17M |
| Shares Change (YoY) | +2.47% |
| Shares Change (QoQ) | +2.86% |
| Owned by Insiders (%) | 0.84% |
| Owned by Institutions (%) | 56.51% |
| Float | 74.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.88 |
| Forward PS | 10.64 |
| PB Ratio | 4.34 |
| P/TBV Ratio | 4.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.69, with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.69 |
| Quick Ratio | 7.38 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -19.89% and return on invested capital (ROIC) is -13.26%.
| Return on Equity (ROE) | -19.89% |
| Return on Assets (ROA) | -11.19% |
| Return on Invested Capital (ROIC) | -13.26% |
| Return on Capital Employed (ROCE) | -22.36% |
| Revenue Per Employee | $429,605 |
| Profits Per Employee | -$257,605 |
| Employee Count | 286 |
| Asset Turnover | 0.27 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zymeworks has paid $6.25 million in taxes.
| Income Tax | 6.25M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.94% in the last 52 weeks. The beta is 1.51, so Zymeworks's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | +38.94% |
| 50-Day Moving Average | 16.56 |
| 200-Day Moving Average | 13.76 |
| Relative Strength Index (RSI) | 66.44 |
| Average Volume (20 Days) | 877,601 |
Short Selling Information
The latest short interest is 7.05 million, so 9.38% of the outstanding shares have been sold short.
| Short Interest | 7.05M |
| Short Previous Month | 6.92M |
| Short % of Shares Out | 9.38% |
| Short % of Float | 9.46% |
| Short Ratio (days to cover) | 10.51 |
Income Statement
In the last 12 months, Zymeworks had revenue of $122.87 million and -$73.68 million in losses. Loss per share was -$0.98.
| Revenue | 122.87M |
| Gross Profit | -20.74M |
| Operating Income | -82.71M |
| Pretax Income | -67.42M |
| Net Income | -73.68M |
| EBITDA | -72.61M |
| EBIT | -82.71M |
| Loss Per Share | -$0.98 |
Full Income StatementBalance Sheet
The company has $281.38 million in cash and $18.68 million in debt, giving a net cash position of $314.70 million or $4.19 per share.
| Cash & Cash Equivalents | 281.38M |
| Total Debt | 18.68M |
| Net Cash | 314.70M |
| Net Cash Per Share | $4.19 |
| Equity (Book Value) | 334.51M |
| Book Value Per Share | 4.47 |
| Working Capital | 257.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$38.71 million and capital expenditures -$1.74 million, giving a free cash flow of -$40.45 million.
| Operating Cash Flow | -38.71M |
| Capital Expenditures | -1.74M |
| Free Cash Flow | -40.45M |
| FCF Per Share | -$0.54 |
Full Cash Flow StatementMargins
Gross margin is -16.88%, with operating and profit margins of -67.32% and -59.96%.
| Gross Margin | -16.88% |
| Operating Margin | -67.32% |
| Pretax Margin | -54.88% |
| Profit Margin | -59.96% |
| EBITDA Margin | -59.09% |
| EBIT Margin | -67.32% |
| FCF Margin | n/a |
Dividends & Yields
Zymeworks does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.47% |
| Shareholder Yield | -2.47% |
| Earnings Yield | -5.14% |
| FCF Yield | -2.82% |
Analyst Forecast
The average price target for Zymeworks is $22.88, which is 19.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.88 |
| Price Target Difference | 19.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 24.49% |
| EPS Growth Forecast (5Y) | 9.53% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zymeworks has an Altman Z-Score of 4.62 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.62 |
| Piotroski F-Score | 4 |
